Inventor · disambiguated record
Robert Janssen
Also filed as: JANSSEN ROBERT · JANSSEN ROBERT S
9 granted patents·19 pending applications·35 citations·filing 2007–2025
87Inventor score
Files withDYNAVAX TECH CORP7THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN5US HEALTH5THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC3HENEINE WALID M1
Top patents by PatentIndex Score
28 records- 0193US11684669B2CpG-adjuvanted SARS-CoV-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 27, 2023·6 cites·30 claims
- 0290US10751412B2Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancerMERCK SHARP & DOHME·Filed 2016·Granted Aug 25, 2020·6 cites·28 claims
- 0388US10335423B2Inhibition of HIV infection through chemoprophylaxisTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN·Filed 2018·Granted Jul 2, 2019·4 cites·19 claims
- 0488US9937191B2Inhibition of HIV infection through chemoprophylaxisUS HEALTH·Filed 2017·Granted Apr 10, 2018·4 cites·19 claims
- 0587US9579333B2Inhibition of HIV infection through chemoprophyalxisUS HEALTH·Filed 2015·Granted Feb 28, 2017·4 cites·17 claims
- 0687US9044509B2Inhibition of HIV infection through chemoprophylaxisHENEINE WALID M·Filed 2007·Granted Jun 2, 2015·10 cites·18 claims
- 0786US2024041906A1Pre-exposure prophylaxis of hiv infectionsUS HEALTH·Filed 2023·Application pending·0 cites
- 0885US2023405027A1Inhibition of hiv infection through chemoprophylaxisUS HEALTH·Filed 2023·Application pending·0 cites
- 0985US2023390313A1Methods of preventing hiv infections in humansUS HEALTH·Filed 2023·Application pending·0 cites
- 1077US12296002B2Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDIGEN VACCINE BIOLOGICS CORP·Filed 2021·Granted May 13, 2025·1 cites·14 claims
- 1176US2022016140A1Inhibition of hiv infection through chemoprophylaxisTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2021·Application pending·0 cites
- 1276US2022016139A1Methods of inhibiting hiv infections by pre-exposure prophylaxisTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN·Filed 2021·Application pending·0 cites
- 1376US2022016141A1Methods of preventing hiv infections in humansTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN·Filed 2021·Application pending·0 cites
- 1475US2021401858A1Pre-exposure prophylaxis of hiv infectionsTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2021·Application pending·0 cites
- 1571US2019269708A1Inhibition of hiv infection through chemoprophylaxisTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2019·Application pending·0 cites
- 1671US2020197421A1Methods of inhibiting hiv infections by pre-exposure prophylaxisTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN·Filed 2020·Application pending·0 cites
- 1771US2020197419A1Pre-exposure prophylaxis of hiv infectionsTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN·Filed 2020·Application pending·0 cites
- 1870US2020197420A1Methods of preventing hiv infections in humansTHE US SECRETARY DEPT OF HEALTH AND HUMAN SERVICE·Filed 2020·Application pending·0 cites
- 1969US12364745B2Immunogenicity of a CpG-adjuvanted recombinant plague vaccineDYNAVAX TECH CORP·Filed 2023·Granted Jul 22, 2025·0 cites·15 claims
- 2064US2025163105A1Immunogenicity of a cpg-adjuvanted herpes zoster vaccineDYNAVAX TECH CORP·Filed 2022·Application pending·0 cites
- 2163US11918648B2Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancerMERCK SHARP & DOHME LLC·Filed 2020·Granted Mar 5, 2024·0 cites·9 claims
- 2261US2025360190A1Immunogenicity of a cpg-adjuvanted recombinant plague vaccineDYNAVAX TECH CORP·Filed 2025·Application pending·0 cites
- 2357US2023110516A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 2454US2023092650A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 2551US2023218740A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 2648US2023072809A1Active booster immunization against tetanus, diphtheria and pertussisDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 2744US2021315991A1Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancerSUREFIRE MEDICAL INC D/B/A TRISALUS LIFE SCIENCES·Filed 2021·Application pending·0 cites
- 2838US2018161427A1Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancerYU YING·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Janssen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →